mTOR Inhibitors [MoA]

Known as: Mammalian Target of Rapamycin Inhibitors, mTOR Inhibitors 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
The mammalian target of rapamycin, mTOR, plays key roles in cell growth and proliferation, acting at the catalytic subunit of two… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
Is this relevant?
Review
2015
Review
2015
The past three decades have seen liver transplantation becoming a major therapeutic approach in the management of end-stage liver… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2014
2014
BACKGROUND The clinical trials that reported benefit of the rapalogs temsirolimus and everolimus in advanced renal cell carcinoma… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 3
Is this relevant?
Review
2014
Review
2014
The mammalian target of rapamycin (mTOR) has emerged as an attractive cancer therapeutic target. Treatment of metastatic renal… (More)
Is this relevant?
Review
2013
Review
2013
PI3K/Akt/mTOR signalling is dysregulated in many cancers, including renal cell carcinoma (RCC), and activation of this pathway… (More)
  • figure 1
  • figure 2
  • table 1
  • table 1
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
To assess incidence and risk factors for de novo cancers (DNCs) after kidney transplant (KT), we carried out a cohort… (More)
Is this relevant?
2013
2013
AIM A number of targeted therapies (TTs) are effective in metastatic renal cell carcinoma (mRCC) but clinical outcomes with the… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2011
2011
BACKGROUND The sequential use of tyrosine kinase inhibitors (TKI) followed by mTOR inhibitors (mTORi) has been recently… (More)
  • table 1
  • table 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
We have previously demonstrated that mTOR inhibitors (MTIs) are active in preclinical models of acute lymphoblastic leukemia (ALL… (More)
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Acute lymphoblastic leukemia (ALL) in adult patients is often resistant to current therapy, making the development of novel… (More)
Is this relevant?